Functionally, the combination treatment led to a significant increase in IFNγ+CD8+ T cells (Fig. 6K), further supporting the anti-tumor immune reprogramming of the TME of HCC induced by this therapeutic approach. This evidence concerns the gene CD8A and neoplasm.